GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Granules India Ltd (BOM:532482) » Definitions » ROE %

Granules India (BOM:532482) ROE % : 16.08% (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Granules India ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Granules India's annualized net income for the quarter that ended in Mar. 2024 was ₹5,186 Mil. Granules India's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ₹32,255 Mil. Therefore, Granules India's annualized ROE % for the quarter that ended in Mar. 2024 was 16.08%.

The historical rank and industry rank for Granules India's ROE % or its related term are showing as below:

BOM:532482' s ROE % Range Over the Past 10 Years
Min: 12.01   Med: 19.48   Max: 27.36
Current: 13.47

During the past 13 years, Granules India's highest ROE % was 27.36%. The lowest was 12.01%. And the median was 19.48%.

BOM:532482's ROE % is ranked better than
78.35% of 993 companies
in the Drug Manufacturers industry
Industry Median: 4.12 vs BOM:532482: 13.47

Granules India ROE % Historical Data

The historical data trend for Granules India's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Granules India ROE % Chart

Granules India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.89 27.36 17.34 19.06 13.38

Granules India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.88 6.76 13.76 16.94 16.08

Competitive Comparison of Granules India's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Granules India's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Granules India's ROE % distribution charts can be found below:

* The bar in red indicates where Granules India's ROE % falls into.



Granules India ROE % Calculation

Granules India's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=4053.1/( (28349.09+32255.44)/ 2 )
=4053.1/30302.265
=13.38 %

Granules India's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=5185.88/( (0+32255.44)/ 1 )
=5185.88/32255.44
=16.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Granules India  (BOM:532482) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=5185.88/32255.44
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5185.88 / 47031.16)*(47031.16 / 55209.82)*(55209.82 / 32255.44)
=Net Margin %*Asset Turnover*Equity Multiplier
=11.03 %*0.8519*1.7116
=ROA %*Equity Multiplier
=9.4 %*1.7116
=16.08 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=5185.88/32255.44
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (5185.88 / 7025.68) * (7025.68 / 8101.04) * (8101.04 / 47031.16) * (47031.16 / 55209.82) * (55209.82 / 32255.44)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7381 * 0.8673 * 17.22 % * 0.8519 * 1.7116
=16.08 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Granules India ROE % Related Terms

Thank you for viewing the detailed overview of Granules India's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Granules India (BOM:532482) Business Description

Traded in Other Exchanges
Address
3rd Block, My Home Hub, 2nd Floor, Madhapur, Hyderabad, TG, IND, 500 081
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the Emerging business that focuses on manufacturing APIs and the US Generics. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and Rest of World.

Granules India (BOM:532482) Headlines

No Headlines